Vincent Kuek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Vincent Kuek has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Laurence C. Cheung
Leukaemia Translational Research Laboratory WA Kids Cancer Centre, The Kids Research Institute Australia Perth Western Australia Australia
5 shared publications - Rishi S. Kotecha
Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation Perth Children's Hospital Perth Western Australia Australia
5 shared publications - Anastasia M. Hughes
Leukaemia Translational Research Laboratory, Telethon Kids Cancer Centre, Telethon Kids Institute, Perth, WA 6009, Australia
2 shared publications Emanuela Ferrari
Leukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia Perth Western Australia Australia
2 shared publications- Jiake Xu
Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology
2 shared publications Jinbo Yuan
School of Biomedical Sciences University of Western Australia Perth Western Australia Australia
2 shared publications
Latest Publications
- Open Access
- 31 March 2026
- Published by Wiley in HemaSphere
- Vol. 10 (4)
Pharmacological inhibition of sclerostin protects bone from B‐cell acute lymphoblastic leukemia‐mediated destruction
- 31 March 2026
- Published by Wiley in HemaSphere
- Vol. 10 (4)
Open AccessPharmacological inhibition of sclerostin protects bone from B‐cell acute lymphoblastic leukemia‐mediated destruction
- 4 December 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (3) , 512-526
Beyond bone: the emerging role of osteoclasts in immune regulation, leukemia development and following myeloablative therapy
Osteoclasts are important regulators of bone remodeling, with an established role in maintaining skeletal homeostasis. The emergence of osteoimmunology has identified osteoclasts as key players in the immune system. In particular, osteoclasts can initiate bi-directional crosstalk mechanisms with hematopoietic stem cells and various immune cells, such as T cells, B cells and NK cells, to influence hematopoiesis and inflammatory response. In recent years, emerging evidence suggests that osteoclasts can remodel the leukemia bone marrow niche, contributing to both leukemogenesis and leukemia-induced bone destruction. In addition, osteoclasts have been implicated as a major source of bone loss following myeloablative therapy for hematopoietic stem cell transplant. An understanding of the mechanisms by which osteoclasts contribute to leukemia-induced and post myeloablative therapy bone loss could pave way for development of new therapeutic approaches in the near future.
- 4 December 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (3) , 512-526
Beyond bone: the emerging role of osteoclasts in immune regulation, leukemia development and following myeloablative therapy
Osteoclasts are important regulators of bone remodeling, with an established role in maintaining skeletal homeostasis. The emergence of osteoimmunology has identified osteoclasts as key players in the immune system. In particular, osteoclasts can initiate bi-directional crosstalk mechanisms with hematopoietic stem cells and various immune cells, such as T cells, B cells and NK cells, to influence hematopoiesis and inflammatory response. In recent years, emerging evidence suggests that osteoclasts can remodel the leukemia bone marrow niche, contributing to both leukemogenesis and leukemia-induced bone destruction. In addition, osteoclasts have been implicated as a major source of bone loss following myeloablative therapy for hematopoietic stem cell transplant. An understanding of the mechanisms by which osteoclasts contribute to leukemia-induced and post myeloablative therapy bone loss could pave way for development of new therapeutic approaches in the near future.
- Open Access
- 9 January 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (2) , 102889
ADR3, a next generation i-body to human RANKL, inhibits osteoclast formation and bone resorption
- 9 January 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (2) , 102889
Open AccessADR3, a next generation i-body to human RANKL, inhibits osteoclast formation and bone resorption
- Open Access
- 15 November 2022
- Published by Springer Nature in Leukemia
- Vol. 37 (1) , 61-71
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. KMT2A-rearranged infant ALL cells are characterized by an abundance of promoter hypermethylation and exhibit high BCL-2 expression, highlighting potential for therapeutic targeting. Here, we show that hypomethylating agents exhibit in vitro additivity when combined with most conventional chemotherapeutic agents. However, in a subset of samples an antagonistic effect was seen between several agents. This was most evident when hypomethylating agents were combined with methotrexate, with upregulation of ATP-binding cassette transporters identified as a potential mechanism. Single agent treatment with azacitidine and decitabine significantly prolonged in vivo survival in KMT2A-rearranged infant ALL xenografts. Treatment of KMT2A-rearranged infant ALL cell lines with azacitidine and decitabine led to differential genome-wide DNA methylation, changes in gene expression and thermal proteome profiling revealed the target protein-binding landscape of these agents. The selective BCL-2 inhibitor, venetoclax, exhibited in vitro additivity in combination with hypomethylating or conventional chemotherapeutic agents. The addition of venetoclax to azacitidine resulted in a significant in vivo survival advantage indicating the therapeutic potential of this combination to improve outcome for infants with KMT2A-rearranged ALL.
- 15 November 2022
- Published by Springer Nature in Leukemia
- Vol. 37 (1) , 61-71
Open AccessPreclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. KMT2A-rearranged infant ALL cells are characterized by an abundance of promoter hypermethylation and exhibit high BCL-2 expression, highlighting potential for therapeutic targeting. Here, we show that hypomethylating agents exhibit in vitro additivity when combined with most conventional chemotherapeutic agents. However, in a subset of samples an antagonistic effect was seen between several agents. This was most evident when hypomethylating agents were combined with methotrexate, with upregulation of ATP-binding cassette transporters identified as a potential mechanism. Single agent treatment with azacitidine and decitabine significantly prolonged in vivo survival in KMT2A-rearranged infant ALL xenografts. Treatment of KMT2A-rearranged infant ALL cell lines with azacitidine and decitabine led to differential genome-wide DNA methylation, changes in gene expression and thermal proteome profiling revealed the target protein-binding landscape of these agents. The selective BCL-2 inhibitor, venetoclax, exhibited in vitro additivity in combination with hypomethylating or conventional chemotherapeutic agents. The addition of venetoclax to azacitidine resulted in a significant in vivo survival advantage indicating the therapeutic potential of this combination to improve outcome for infants with KMT2A-rearranged ALL.
- Open Access
- 7 September 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 154, 113622
Thiaplakortone B attenuates RANKL‐induced NF‐κB and MAPK signaling and dampens OVX‐induced bone loss in mice
- 7 September 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 154, 113622
Open AccessThiaplakortone B attenuates RANKL‐induced NF‐κB and MAPK signaling and dampens OVX‐induced bone loss in mice
- Open Access
The Bone Marrow Microenvironment in B-Cell Development and Malignancy
B lymphopoiesis is characterized by progressive loss of multipotent potential in hematopoietic stem cells, followed by commitment to differentiate into B cells, which mediate the humoral response of the adaptive immune system. This process is tightly regulated by spatially distinct bone marrow niches where cells, including mesenchymal stem and progenitor cells, endothelial cells, osteoblasts, osteoclasts, and adipocytes, interact with B-cell progenitors to direct their proliferation and differentiation. Recently, the B-cell niche has been implicated in initiating and facilitating B-cell precursor acute lymphoblastic leukemia. Leukemic cells are also capable of remodeling the B-cell niche to promote their growth and survival and evade treatment. Here, we discuss the major cellular components of bone marrow niches for B lymphopoiesis and the role of the malignant B-cell niche in disease development, treatment resistance and relapse. Further understanding of the crosstalk between leukemic cells and bone marrow niche cells will enable development of additional therapeutic strategies that target the niches in order to hinder leukemia progression.
Open AccessThe Bone Marrow Microenvironment in B-Cell Development and Malignancy
B lymphopoiesis is characterized by progressive loss of multipotent potential in hematopoietic stem cells, followed by commitment to differentiate into B cells, which mediate the humoral response of the adaptive immune system. This process is tightly regulated by spatially distinct bone marrow niches where cells, including mesenchymal stem and progenitor cells, endothelial cells, osteoblasts, osteoclasts, and adipocytes, interact with B-cell progenitors to direct their proliferation and differentiation. Recently, the B-cell niche has been implicated in initiating and facilitating B-cell precursor acute lymphoblastic leukemia. Leukemic cells are also capable of remodeling the B-cell niche to promote their growth and survival and evade treatment. Here, we discuss the major cellular components of bone marrow niches for B lymphopoiesis and the role of the malignant B-cell niche in disease development, treatment resistance and relapse. Further understanding of the crosstalk between leukemic cells and bone marrow niche cells will enable development of additional therapeutic strategies that target the niches in order to hinder leukemia progression.
- Open Access
- 26 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 6888
Therapeutic Targeting of the Leukaemia Microenvironment
In recent decades, the conduct of uniform prospective clinical trials has led to improved remission rates and survival for patients with acute myeloid leukaemia and acute lymphoblastic leukaemia. However, high-risk patients continue to have inferior outcomes, where chemoresistance and relapse are common due to the survival mechanisms utilised by leukaemic cells. One such mechanism is through hijacking of the bone marrow microenvironment, where healthy haematopoietic machinery is transformed or remodelled into a hiding ground or “sanctuary” where leukaemic cells can escape chemotherapy-induced cytotoxicity. The bone marrow microenvironment, which consists of endosteal and vascular niches, can support leukaemogenesis through intercellular “crosstalk” with niche cells, including mesenchymal stem cells, endothelial cells, osteoblasts, and osteoclasts. Here, we summarise the regulatory mechanisms associated with leukaemia–bone marrow niche interaction and provide a comprehensive review of the key therapeutics that target CXCL12/CXCR4, Notch, Wnt/b-catenin, and hypoxia-related signalling pathways within the leukaemic niches and agents involved in remodelling of niche bone and vasculature. From a therapeutic perspective, targeting these cellular interactions is an exciting novel strategy for enhancing treatment efficacy, and further clinical application has significant potential to improve the outcome of patients with leukaemia.
- 26 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 6888
Open AccessTherapeutic Targeting of the Leukaemia Microenvironment
In recent decades, the conduct of uniform prospective clinical trials has led to improved remission rates and survival for patients with acute myeloid leukaemia and acute lymphoblastic leukaemia. However, high-risk patients continue to have inferior outcomes, where chemoresistance and relapse are common due to the survival mechanisms utilised by leukaemic cells. One such mechanism is through hijacking of the bone marrow microenvironment, where healthy haematopoietic machinery is transformed or remodelled into a hiding ground or “sanctuary” where leukaemic cells can escape chemotherapy-induced cytotoxicity. The bone marrow microenvironment, which consists of endosteal and vascular niches, can support leukaemogenesis through intercellular “crosstalk” with niche cells, including mesenchymal stem cells, endothelial cells, osteoblasts, and osteoclasts. Here, we summarise the regulatory mechanisms associated with leukaemia–bone marrow niche interaction and provide a comprehensive review of the key therapeutics that target CXCL12/CXCR4, Notch, Wnt/b-catenin, and hypoxia-related signalling pathways within the leukaemic niches and agents involved in remodelling of niche bone and vasculature. From a therapeutic perspective, targeting these cellular interactions is an exciting novel strategy for enhancing treatment efficacy, and further clinical application has significant potential to improve the outcome of patients with leukaemia.